JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer Study

Shares of Jazz Pharmaceuticals (JAZZ) rose nearly 6% on Tuesday after it reported positive top-line results from the phase III IMforte study, which evaluated Zepzelca (lurbinectedin), combined with Roche's (RHHBY) Tecentriq (atezolizumab), in patients with extensive-stage small cell lung cancer (ES-SCLC). The Roche-sponsored IMforte study achieved statistically significant improvement in the primary endpoints of overall survival and progression-free survival. Treatment with the Zepzelca-Tecentriq combinatio ...